Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.86 USD | +2.10% | +9.60% | +67.27% |
04-19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
03-28 | Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target | MT |
End-of-day quotes
Compared values
Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
---|---|---|---|---|---|---|---|---|---|---|---|
MERUS N.V. | Bio Therapeutic Drugs | +2.43% | +9.60% | +67.27% | +142.11% | +193.55% | 2.64B |
Technical Rankings Surperformance
- Stock Market
- Equities
- MRUS Stock
- Charts Merus N.V.
- Comparison Chart